<DOC>
	<DOC>NCT02469883</DOC>
	<brief_summary>This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.</brief_summary>
	<brief_title>A Study of Sinotecean on Tolerance and Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>late malignant tumor patients diagnosed with the pathological and/or cytological; lack of the standard treatment or treatment failure; 1865years, ECOG:01,expected survival period &gt;3 months; main organs function is normal; signed and dated informed consent participated in other clinical trials in four weeks; currently under other effective treatment; end of antitumor treatment within 4 weeks(end of Nitrosourea/Mitomycin within 6 weeks); AE â‰¥ Grade 2(according to NCICTC 4.0),except hair loss; with ischemic heart disease, heart failure, severe arrhythmia, cerebrovascular disease, asthma, severe infections, active peptic ulcer; urine protein: ++, and urinary in 24 hours &gt; 1.0g; uncontrolled primary or metastatic brain; have immunodeficiency history; according to the researcher's judgment,there are concomitant diseases which will seriously endanger the patients or obstruct the patients to complete the clinical trial;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>